Article
The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
Acta neurologica Scandinavica - 1 Jan 2014
Møller M, Søndergaard H B, Koch-Henriksen N, Sorensen P S, Sellebjerg F, Oturai A B
Abstract excerpt
OBJECTIVE: The chemokine receptor CCR5 may be important for the recruitment of pathogenic T cells to the CNS in multiple sclerosis (MS). We hypothesized that this chemokine receptor might still be important for T-cell migration during treatment with anti-very late antigen (VLA)-4 antibody. We therefore analysed whether natalizumab-treated MS patients carrying the CCR5 Δ32 deletion allele, which results in reduced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.